A nonsteroidal intestinal-restricted FXR ligand known as Fexaramine has shown to ameliorate liver injury and hepatic steatosis in mice on an HFD and shows potential for the treatment of CMD [133,134]. This evidence concerns the gene NR1H4 and Hepatic steatosis.